Whole-Genome Sequencing Assay Detects HPV
November 28, 2025
-
4 min
HPV-DeepSeek, a next-generation liquid biopsy test, shows exceptional sensitivity (98.7%) and specificity (99.1%) for detecting HPV-related circulating tumor DNA in over 400 patients. Presented by Dr. Adam S. Fisch at the AMP 2025 meeting, the assay targets 43 HPV genotypes and has potential applications in early diagnosis, treatment monitoring, and assessment of residual disease across various cancer types, including oropharyngeal and cervical cancers, while providing insights into specific mutations and viral integration patterns.
1. HPV-DeepSeek assay shows 98.7% sensitivity, 99.1% specificity. 2. Targets 43 HPV genotypes, crucial for early cancer detection. 3. Study involved 224 patients with HPV-associated squamous cell carcinoma. 4. High median genome coverage near 100% in true-positive cases. 5. Reports PIK3CA mutations and viral integration patterns. 6. Observations align with established cancer-site-specific tendencies. 7. Potential applications in treatment monitoring and assessing residual disease.
Listen Tab content
